慢性肾衰竭的透析治疗:综述
本综述总结慢性肾衰竭维持性透析的现状:全球超过350万人、美国54万人接受维持性血液透析或腹膜透析,启动透析后5年生存率约40%。无推荐的eGFR启动阈值,启动时机由尿毒症症状、容量负荷、eGFR恶化、代谢性酸中毒和高钾血症等共同决定,需医患共同决策。一项随机临床试验报告较高eGFR(10-14 mL/min/1.73 m2)与较低eGFR(5-7 mL/min/1.73 m2)启动透析无死亡率获益;观察性数据显示血液透析与腹膜透析5年死亡率无差异。心血管和感染相关并发症常见,贫血、高磷血症、低钙血症和高血压常需药物治疗。
要点
- 无推荐的eGFR阈值用于启动透析,启动时机应基于尿毒症症状、容量负荷、eGFR恶化、代谢性酸中毒和高钾血症,并结合医患共同决策。
- 一项随机临床试验报告较高eGFR(10-14 mL/min/1.73 m2)与较低eGFR(5-7 mL/min/1.73 m2)启动透析无死亡率获益。
- 观察性数据显示血液透析与腹膜透析5年死亡率无差异。
- 美国血液透析导管相关血流感染发生率为每1000导管日1.1至5.5例,约50%患者在置管后6个月内发生。
- 腹膜透析腹膜炎发生率为每患者年0.26例,约30%患者在腹膜透析治疗第一年内发生。
适用人群与场景
- 全球超过350万人、美国54万人因慢性肾衰竭接受维持性血液透析或腹膜透析。
- 慢性肾衰竭相关系统性并发症(贫血、高磷血症、低钙血症、高血压)常需药物治疗的人群。
诊断标准与关键阈值
- 无推荐的eGFR阈值用于启动透析。
- 启动透析的时机参考:持续性尿毒症体征和症状(如恶心、乏力)和容量负荷过重(如呼吸困难、外周水肿)、eGFR恶化、代谢性酸中毒和高钾血症。
- 患者-临床医生共同决策应帮助确定何时启动透析。
处置流程与药物剂量
- 血液透析和腹膜透析清除代谢废物和多余体液并重新平衡电解质以维持生命。
- 慢性肾衰竭相关系统性并发症如贫血、高磷血症、低钙血症和高血压常需药物治疗。
- 透析中低血压、难治性症状(如肌肉痉挛、瘙痒)和透析通路功能障碍可能干扰透析的实施。
红旗征与不能漏的情况
- 心血管并发症(如心律失常、心脏骤停)是维持性透析的常见并发症。
- 感染相关并发症是维持性透析的常见并发症;美国血液透析导管相关血流感染发生率为每1000导管日1.1至5.5例,约50%患者在置管后6个月内发生。
- 腹膜透析腹膜炎发生率为每患者年0.26例,约30%患者在腹膜透析治疗第一年内发生。
研究设计与关键结果
- 综述:全球超过350万人、美国54万人接受维持性血液透析或腹膜透析;启动维持性透析后5年生存率约40%。
- 随机临床试验报告较高eGFR(10-14 mL/min/1.73 m2)与较低eGFR(5-7 mL/min/1.73 m2)启动透析无死亡率获益。
- 观察性数据提示血液透析与腹膜透析5年死亡率无差异。
- 美国血液透析导管相关血流感染发生率为每1000导管日1.1至5.5例,约50%患者在置管后6个月内发生。
- 腹膜透析腹膜炎发生率为每患者年0.26例,约30%患者在腹膜透析治疗第一年内发生。
- 2021年美国超过54万患者因慢性肾衰竭接受维持性血液透析或腹膜透析。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 启动透析的时机不应仅依据eGFR阈值,应综合评估尿毒症症状、容量负荷、eGFR轨迹、代谢性酸中毒和高钾血症,并与患者共同决策。
- 选择血液透析或腹膜透析时,可参考观察性数据显示两者5年死亡率无差异,并结合患者症状、实验室趋势、患者偏好以及治疗费用和可及性。
- 维持性透析患者需关注心血管和感染相关并发症,以及贫血、高磷血症、低钙血症和高血压的药物治疗。
指南或共识出处
- JAMA综述:慢性肾衰竭的透析治疗(Dialysis for Chronic Kidney Failure: A Review)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: More than 3.5 million people worldwide and 540 000 individuals in the US receive maintenance hemodialysis or peritoneal dialysis for the treatment of chronic kidney failure. The 5-year survival rate is approximately 40% after initiation of maintenance dialysis.
OBSERVATIONS: Hemodialysis and peritoneal dialysis remove metabolic waste and excess body water and rebalance electrolytes to sustain life. There is no recommended estimated glomerular filtration rate (eGFR) threshold for initiating dialysis, and patient-clinician shared decision-making should help determine when to initiate dialysis. Persistent signs and symptoms of uremia (eg, nausea, fatigue) and volume overload (eg, dyspnea, peripheral edema), worsening eGFR, metabolic acidosis, and hyperkalemia inform the timing of therapy initiation. A randomized clinical trial reported no mortality benefit to starting dialysis at higher eGFR (10-14 mL/min/1.73 m2) vs lower eGFR (5-7 mL/min/1.73 m2) levels. Observational data suggested no differences in 5-year mortality with use of hemodialysis vs peritoneal dialysis. Cardiovascular (eg, arrhythmias, cardiac arrest) and infection-related complications of maintenance dialysis are common. In the US, hemodialysis catheter-related bloodstream infections occur at a rate of 1.1 to 5.5 episodes per 1000 catheter-days and affect approximately 50% of patients within 6 months of catheter placement. Peritonitis occurs at a rate of 0.26 episodes per patient-year and affects about 30% of individuals in the first year of peritoneal dialysis therapy. Chronic kidney failure-related systemic complications, such as anemia, hyperphosphatemia, hypocalcemia, and hypertension, often require pharmacologic treatment. Hypotension during dialysis, refractory symptoms (eg, muscle cramps, itching), and malfunction of dialysis access can interfere with delivery of dialysis.
CONCLUSIONS AND RELEVANCE: In 2021, more than 540 000 patients in the US received maintenance hemodialysis or peritoneal dialysis for treatment of chronic kidney failure. Five-year survival rate after initiation of maintenance dialysis is approximately 40%, and the mortality rate is similar with hemodialysis and peritoneal dialysis. Decisions about dialysis initiation timing and modality are influenced by patient symptoms, laboratory trajectories, patient preferences, and therapy cost and availability and should include shared decision-making.
参考来源
- Flythe JE, Watnick S. Dialysis for Chronic Kidney Failure: A Review. JAMA. 2024. PMID: 39356511. doi:10.1001/jama.2024.16338
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。